Showing results (11-20 of 205) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|January 9, 2007
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)Alison Reid, Laura Vidal, Heather Shaw, et al.Cancer Discovery|May 16, 2012
Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progressVictor Moreno Garcia, Philippe A Cassier, Johann de BonoTrends in Cancer|July 26, 2017
The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic LethalityS Percy Ivy, Johann de Bono, Elise C KohnEuropean Journal of Cancer (Oxford, England : 1990)|November 18, 2005
Making sense of antisenseLaura Vidal, Sarah Blagden, Gerhardt Attard, et al.Hematology/Oncology Clinics of North America|November 6, 2013
Management of patients with castration-resistant diseaseCarmel Pezaro, Aurelius Omlin, David Lorente, et al.Current Opinion in Molecular Therapeutics|October 7, 2009
Reovirus: Rationale and clinical trial updateRohit Lal, Dean Harris, Sophie Postel-Vinay, et al.Clinical Lung Cancer|September 15, 2005
Histone deacetylase inhibitors: emerging anticancer therapeutic agents?Rebecca Kristeleit, Peter Fong, G Wynne Aherne, et al.BJU International|March 21, 2012
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunitiesHeather Payne, Amit Bahl, Malcolm Mason, et al.Cancer Metastasis Reviews|January 24, 2014
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeuticsDeborah Mukherji, Aurelius Omlin, Carmel Pezaro, et al.Cancer Treatment Reviews|August 21, 2013
Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agentsAmit Bahl, Susan Masson, Alison Birtle, et al.Pageof 21